Recombinant human activated protein C

International Journal of Antimicrobial Agents

Volumn 28, Issue 2, 2006, Pages 90-94

  Hughes, Martin ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Drotrecogin alfa activated; Drug therapy; Pathophysiology; Recombinant human activated protein C; Sepsis syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DROTRECOGIN;

APOPTOSIS; BLEEDING; CLINICAL TRIAL; CLONAL ANERGY; DRUG FATALITY; EVIDENCE BASED MEDICINE; HUMAN; IMMUNITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; SHORT SURVEY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FIBRINOLYTIC AGENTS; HUMANS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; TREATMENT OUTCOME;

EID: 33746298889     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.05.021     Document Type: Short Survey

References (23)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., and Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001) 1303-1310
2. Martin G.S., Mannino D.M., Eaton S., and Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003) 1546-1554
3. Bernard G.R., Vincent J.L., Laterre P.F., et al., Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
4. Eichacker P.Q., and Natanson C. Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials. Crit Care Med 31 Suppl. (2003) S94-S96
5. Ely E.W., Bernard G.R., and Vincent J.L. Activated protein C for severe sepsis. N Engl J Med 347 (2002) 1035-1036
6. Prendergast T.J., and Luce J.M. Increasing incidence of withholding and withdrawal of life support from the critically ill. Am J Respir Crit Care Med 155 (2005) 15-20
7. Oberholzer A., Oberholzer C., and Moldawer L.L. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 16 (2001) 83-96
8. Ertel W., Kremer J.-P., Kenney J., et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood 85 (1995) 1341-1347
9. Heidecke C.D., Hensler T., Weighardt H., et al. Selective defects of T lymphocyte function in patients with lethal intraabdominal infection. Am J Surg 178 (1999) 288-292
10. Hotchkiss R.S., Swanson P.E., Freeman B.D., et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 27 (1999) 1230-1251
11. Hotchkiss R.S., Tinsley K.W., Swanson P.E., et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 168 (2002) 2493-2500
12. Hotchkiss R.S., Tinsley K.W., Swanson P.E., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 166 (2001) 6952-6963
13. Hotchkiss R.S., and Karl I.E. The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003) 138-150
14. Eisenberg P. Re: Discontinuation of study F1K-MC-EVBP, investigation of the efficacy and safety of drotrecogin alfa (activated) in paediatric severe sepsis (letter). http://www.fda.gov/medwatch/SAFETY/2005/xigris_dearhcp_4-21-05.htm [accessed 12 May 2006].
15. Eisenberg P. Re: Important drug warning (letter). http://www.fda.gov/medwatch/SAFETY/2005/xigris_DHCP.htm [accessed 12 May 2006].
16. Abraham E., Laterre P.F., Garg R., et al., Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
17. Eichacker P.Q., Danner R.L., Suffredini A.F., Cui X., and Natanson C. Reassessing recombinant human activated protein C for sepsis: time for a new randomised controlled trial. Crit Care Med 33 (2005) 2426-2428
18. Angus D.C., Laterre P.F., Helterbrand J., et al., PROWESS Investigators. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis. Crit Care Med 32 (2004) 2199-2206
19. Tanzi M. Use of drotrecogin alfa activated for the treatment of severe sepsis - medical use evaluation by Novation - the medical supply company of VHA & UHC. Novation, 2004.
20. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open label trial ENHANCE: further evidence for survival and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
21. Dellinger R.P. Recombinant activated protein C: decisions for administration. Crit Care Med 34 (2006) 530-531
22. Poses R.M., Smith W.R., McClish D.K., et al. Physicians' survival predictions for patients with acute congestive heart failure. Arch Intern Med 157 (1997) 1001-1007
23. Rocker G., Cook D., Sjokvist P., et al., Level of Cave Study Investigators; Canadian Critical Care Trials Group. Clinician predictions of intensive care unit mortality. Crit Care Med 32 (2006) 1149-1154